Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of APD334 in moderate to severe active ulcerative colitis
MOH_2017-03-22_000271Phase 2Recruiting
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of etrasimod in autoimmune colitis (3 arms), sponsored by Arena Pharmaceuticals, Inc. Started Feb 2016; status: recruiting.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2017-03-22_000271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-22_000271.